Navigation Links
MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Date:10/5/2007

NEW JERSEY, Oct. 5 /PRNewswire-FirstCall/ - MaxLife Fund Corp. (OTC:MXFD), announced today that they have retained the law firm of Anslow & Jaclin, LLP to review the company options to be listed on the NASDAQ Capital Market.

The Company believes that listing on the NASDAQ Capital Market will provide greater visibility for our operations, and will vastly improve the flow of information to our shareholders and potential investors.

MaxLife Fund Corp. is a fund designated to excel in the Life Settlement sector and to partner with revenue generating businesses that are profitable, in the health sector. MaxLife is committed to create value for its shareholders by becoming one of the leading funds in the life and health sector.

Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this news release.

For further information contact:

MaxLife Fund Corp.

1-866-752-5557


'/>"/>
SOURCE MaxLife Fund Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. The Memory Retains Things that We Have forgotten
3. FDA may speed review of new drugs
4. Scientists review SARS
5. US Reviews Risks Of Tamiflu After 12 Children Die
6. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
7. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
8. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
9. Thumbs up in weight loss for vegetarian diets: scientific review
10. FDA Accords Priority Review For Pediatric Crohns Disease Drug
11. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic ... manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: